-- Nicolas Hulscher, MPH
https://thefocalpoints.com/p/new-study-pfizer-recipients-face
Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or m-RNA-1273 among Adults Living in Florida
https://www.reddit.com/r/unvaccinated/comments/1kb22ie/twelvemonth_allcause_mortality_after_initial
"It has become painfully obvious that as a result of Big Pharma-driven vaccine ideology, these products do not receive the safety scrutiny they should.”
https://x.com/flsurgeongen/status/1917336608224748016?s=46&t=fF7mdVePcx39XTZSFBJtsA
https://www.medrxiv.org/content/10.1101/2025.04.25.25326460v1
This study compared 12-month all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality risks among Florida adults vaccinated with either Pfizer-BioNTech’s BNT162b2 or Moderna’s mRNA-1273 mRNA vaccines.
A matched cohort study used Florida’s public health databases, analyzing vaccination records, sociodemographic data, and vital statistics for noninstitutionalized adults vaccinated between December 18, 2020, and August 31, 2021.
From 9,162,484 eligible adults, 1,470,100 were matched 1:1 (735,050 per vaccine group) based on age, sex, race, ethnicity, vaccination month, site type, and census tract.
All-Cause Mortality: BNT162b2 recipients had a higher risk (847.2 vs. 617.9 deaths per 100,000; OR 1.384 [95% CI: 1.331, 1.439]).
Cardiovascular Mortality: Higher for BNT162b2 (248.7 vs. 162.4 deaths per 100,000; OR 1.540 [95% CI: 1.431, 1.657]).
COVID-19 Mortality: Higher for BNT162b2 (55.5 vs. 29.5 deaths per 100,000; OR 1.882 [95% CI: 1.596, 2.220]).
Non-COVID-19 Mortality: Higher for BNT162b2 (791.6 vs. 588.4 deaths per 100,000; OR 1.356 [95% CI: 1.303, 1.412]).
The increased mortality risk was most pronounced in those over 60.
Negative control outcomes showed no significant residual confounding.
BNT162b2 recipients faced significantly higher 12-month mortality risks compared to mRNA-1273 recipients, suggesting potential differential non-specific effects of these vaccines. The findings raise concerns about adverse effects on all-cause and cardiovascular mortality, emphasizing the need to evaluate vaccines for clinical endpoints beyond their target diseases.
Limitations: Matching omitted comorbidities, potentially introducing bias, and reduced the study population. Death certificate misclassification could affect outcome accuracy, though not differentially between groups.
Implications: These results highlight the importance of considering non-specific vaccine effects in public health policies and vaccine evaluation frameworks."
RESOURCES:
NEW STUDY — Pfizer Recipients Face 37% Higher Risk of Death Than Moderna Recipients
https://www.thefocalpoints.com/p/new-study-pfizer-recipients-face
STUDY: “Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida” w
https://www.medrxiv.org/content/10.1101/2025.04.25.25326460v1
#SubpoenaFauci #WHO #Fauci #GainofFunctionResearch #COVID19 #COVID19ORIGINS #coronavirus #covid19vaccine #VaccineMandates #Pandemic #Gaslighting
#Propaganda #fraud #hoax #DemExit #USPolitics #Green #Progressive #Libertarian #Solidarity
